Skip to content
PubMed This is a summary of 50 peer-reviewed journal articles Updated
Neurology

Free Sialic Acid Storage Disease (FSASD): A Patient Guide

At a Glance

Free sialic acid storage disease (FSASD) is a rare genetic disorder caused by a change in a gene called SLC17A5, which traps sialic acid inside cells. It ranges from severe infantile disease to slower-progressing Salla disease, so care is tailored to symptoms and focused on quality of life.

Free Sialic Acid Storage Disease (FSASD) is an ultra-rare genetic condition that changes how cells manage and recycle essential materials. It belongs to a group of conditions known as lysosomal storage disorders, where the “recycling centers” of the cells (lysosomes) cannot properly export a sugar called sialic acid. This occurs because of a pathogenic variant in the SLC17A5 gene, which provides the instructions for a transport protein called sialin. When sialin is missing or malfunctioning, sialic acid becomes trapped, building up over time and disrupting the normal function of cells throughout the body, particularly in the brain and nervous system [1].

The condition exists on a broad clinical spectrum, meaning it can look very different from one person to another. At one end is the more severe Infantile Free Sialic Acid Storage Disease (ISSD), which often affects multiple organs and is apparent from birth or early infancy. At the other end is Salla disease, a more slowly progressive form that typically begins in infancy with developmental delays and coordination challenges, and affects individuals into adulthood. Many fall somewhere in the middle, experiencing a unique combination of symptoms that may evolve over time. Understanding this spectrum is vital because it helps your medical team anticipate specific needs and tailor care accordingly [2][3].

Living with FSASD requires a shift toward proactive, comprehensive support. Because the disease affects movement, communication, and sensory processing, a multidisciplinary care team—including neurologists, geneticists, and various therapists—is the cornerstone of management. While there is not yet a cure that addresses the underlying genetic cause, high-quality supportive care can significantly improve comfort and independence. This involves managing symptoms like muscle stiffness and coordination issues, ensuring nutritional safety, and utilizing communication tools [1][4].

An accurate genetic diagnosis is a powerful tool, providing the clarity needed to navigate this complex journey. It allows you to connect with a global community of researchers and other families who understand the unique challenges of an ultra-rare diagnosis. While the road ahead may feel uncertain, focusing on quality of life and building a dedicated medical “home” ensures the best possible support system. Your observations are essential, and your multidisciplinary team should help share the work of managing this complex condition [5][6].

Common questions in this guide

What is Free Sialic Acid Storage Disease (FSASD)?
FSASD is an ultra-rare genetic condition in which a change in the SLC17A5 gene affects sialin, a protein that helps cells move sialic acid out of their recycling centers. Sialic acid can then build up inside cells and disrupt their normal function, especially in the brain and nervous system. The condition can affect people in different ways and may begin in infancy.
Are Salla disease and infantile free sialic acid storage disease different conditions?
They are different clinical forms within the FSASD spectrum. Infantile Free Sialic Acid Storage Disease is generally more severe and appears at birth or in early infancy, while Salla disease usually progresses more slowly and can affect people into adulthood. Some people have features that fall between these forms.
How can genetic testing help with FSASD?
Genetic testing can identify a disease-causing variant in SLC17A5, the gene that provides instructions for sialin. A confirmed genetic diagnosis can help the medical team understand where a person may fit on the FSASD spectrum, plan support, and connect the family with specialized centers or researchers.
What treatments are available for FSASD?
There is not yet a cure that corrects the underlying genetic cause. Treatment is supportive and may include a multidisciplinary care team, management of muscle stiffness and coordination problems, attention to nutritional safety, and communication tools. Care is tailored to the person's symptoms and daily goals.
What kind of care team is needed for someone with FSASD?
Care commonly involves a neurologist, geneticist, and therapists, with other specialists added according to the person's needs. This team can support movement, communication, nutrition, comfort, and independence while sharing responsibility for long-term care.
How can FSASD affect people differently over time?
FSASD has a broad clinical spectrum, so symptoms and their progression vary from person to person. Changes may involve development, movement, coordination, communication, and sensory processing. Regular assessment by a multidisciplinary team helps anticipate needs and tailor support as they evolve.

Get notified when new evidence is published on Free sialic acid storage disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (6)
  1. 1

    Free sialic acid storage disorder: Progress and promise.

    Huizing M, Hackbarth ME, Adams DR, et al.

    Neuroscience letters 2021; (755()):135896 doi:10.1016/j.neulet.2021.135896.

    PMID: 33862140
  2. 2

    A cross-sectional quantitative analysis of the natural history of free sialic acid storage disease-an ultra-orphan multisystemic lysosomal storage disorder.

    Zielonka M, Garbade SF, Kölker S, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(2)):347-352 doi:10.1038/s41436-018-0051-3.

    PMID: 29875421
  3. 3

    A New Patient With Intermediate Severe Salla Disease With Hypomyelination: A Literature Review for Salla Disease.

    Barmherzig R, Bullivant G, Cordeiro D, et al.

    Pediatric neurology 2017; (74()):87-91.e2 doi:10.1016/j.pediatrneurol.2017.05.022.

    PMID: 28662915
  4. 4

    A 13-year follow-up of Finnish patients with Salla disease.

    Paavola LE, Remes AM, Harila MJ, et al.

    Journal of neurodevelopmental disorders 2015; (7(1)):20 doi:10.1186/s11689-015-9116-7.

    PMID: 26171070
  5. 5

    A systematic review and integrative sequential explanatory narrative synthesis: The psychosocial impact of parenting a child with a lysosomal storage disorder.

    Hassall S, Smith DM, Rust S, Wittkowski A

    Journal of inherited metabolic disease 2022; (45(3)):406-416 doi:10.1002/jimd.12482.

    PMID: 35124835
  6. 6

    Alone in a Crowd? Parents of Children with Rare Diseases' Experiences of Navigating the Healthcare System.

    Baumbusch J, Mayer S, Sloan-Yip I

    Journal of genetic counseling 2018; doi:10.1007/s10897-018-0294-9.

    PMID: 30128673

This page provides general information about FSASD for educational purposes only and does not constitute medical advice. A neurologist, geneticist, or other qualified clinician should interpret your genetic results and help plan care for your specific situation.